Abstract Details

Title Poor Physical Performance Increases the Risk of Dementia in the Oldest-Old

Topic Aging and Dementia

Presentation(s) P03 - (-)

Poster/Presentation
Number 096

Objective

Background BACKGROUND: We have previously reported a strong, dose-dependent cross-sectional relationship between poor physical performance and odds of dementia, where poorer physical performance was associated with increased odds of prevalent dementia.

Design/Methods DESIGN/METHODS: The 90+ Study is a population based investigation of dementia in people aged 90 and older. 594 participants from The 90+ Study were included in this study. Physical performance measures (5 chair-stands, 10-second balance, 4-m walk and handgrip) were scored from 0-4 (0= unable to perform, 4= best performance). The outcome was dementia, diagnosed by applying DSM-IV criteria. Hazard Ratios (HR) for dementia in relation to physical performance were estimated by Cox Regression after adjustment for age and gender.

Results RESULTS: At baseline, all participants were non-demented (normal: 57%, cognitively impaired non-demented: 43%), mostly women (69%) with an average age of 93.3 (range 90.0-103.0) years. The average length of follow-up was 2.6 (range 0.1-9.0) years. Poor physical performance in all measures was significantly associated with increased risk of incident dementia. HR for every unit decrease in physical performance score were 1.18 for 5 chair-stands, 1.27 for balance, 1.35 for 4-m walk, 1.17 for handgrip (all p<0.05). In a subanalysis that only included participants with normal baseline cognitive status HRs remained unchanged for 5 chair-stand (HR=1.13, p=0.14) and balance (HR=1.27 p=0.004), but were lower for 4-m walk (HR 1.22 p=0.04), and slightly higher for handgrip (HR=1.27 p=0.004).

Conclusions CONCLUSIONS: In this cohort of people over age 90, participants with poor physical performance are at increased risk of developing dementia. Further evaluation is still required to determine if poor physical performance is a modifiable risk factor or merely a different manifestation of the same neurodegenerative process which is detected before cognitive impairment and dementia.

Authors/Disclosures
Szofia S. Bullain, MD (F. Hoffmann - La Roche Ltd.) PRESENTER	Dr. Bullain has received personal compensation for serving as an employee of F. Hoffmann - La Roche Ltd.. Dr. Bullain has received stock or an ownership interest from F. Hoffmann - La Roche Ltd..
Maria Corrada, PhD (University of California Irvine)	The institution of Dr. Corrada has received research support from NIH.
Gavin Giovannoni, MD (QMUL)	Dr. Giovannoni has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Merck KGaA. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche-Genentech. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Moderna. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sandoz. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Astoria Biologica. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Zenas. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Giovannoni has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Medscape.
Claudia Kawas, MD (University of California, Irvine)	The institution of Dr. Kawas has received research support from NIH.
	No disclosure on file

��ɫ��

��ɫ��